Literature DB >> 6156048

Disease-induced changes in the plasma binding of basic drugs.

K M Piafsky.   

Abstract

The plasma binding of basic (cationic) drugs differs from that of the more completely studied acidic drugs. Basic drugs associate with a number of plasma constituents. alpha 1-Acid glycoprotein, lipoprotein, and albumin all appear to play an important role in the binding of most of these drugs. Acidic drugs bind largely to albumin. The variation in plasma albumin is relatively narrow and is almost always in the direction of decreased concentrations. alpha 1-Acid glycoprotein and lipoproteins show large fluctuations due both to physiological and pathological conditions. Decreases and increases in concentration have been observed. Associated with these changes in binding proteins, both decreases and increases in plasma binding of basic drugs have been recorded. Increased binding with disease appears to be virtually unique to basic drugs. The implications of these newly described disease-induced increases in plasma binding have yet to be explored. With the limited information in hand the following consequences are predicted. Increased binding will tend to decrease the volume of distribution of total (bound plus free) drug. The clearance will be unchanged or decreased depending upon the initial clearance of the drug and the avidity of the protein binding. As the half-life depends upon both clearance and volume of distribution, changes in it will be variable, depending upon changes in these two parameters. It is predicted that the area under the free drug plasma concentration-time curve will decrease with increasing binding after an intravenous dose while it will be unchanged after an oral dose. The relationship of total drug plasma concentration to free drug concentration will change with changes in binding. Thus plasma concentration monitoring of drug therapy by use of total drug concentrations will be inaccurate in situations in which large variations in binding occur. Misinterpretations of both therapeutic monitoring and pharmacokinetics studies in disease states with altered binding are likely unless these changes are appreciated.

Mesh:

Substances:

Year:  1980        PMID: 6156048     DOI: 10.2165/00003088-198005030-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  106 in total

1.  Serum albumin and lipoproteins as the quinidine binding molecules in normal human sera.

Authors:  O G Nilsen
Journal:  Biochem Pharmacol       Date:  1976-05-01       Impact factor: 5.858

2.  The protein binding of some drugs in plasma from patients with alcoholic liver disease.

Authors:  M Affrime; M M Reidenberg
Journal:  Eur J Clin Pharmacol       Date:  1975-04-04       Impact factor: 2.953

Review 3.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

4.  Perfusion-limited of plasma drug binding on hepatic drug extraction.

Authors:  D G Shand; R H Cotham; G R Wilkinson
Journal:  Life Sci       Date:  1976-07-01       Impact factor: 5.037

5.  Pentazocine binding to blood cells and plasma proteins.

Authors:  M Ehrnebo; S Agurell; L O Boréus; E Gordon; U Lönroth
Journal:  Clin Pharmacol Ther       Date:  1974-09       Impact factor: 6.875

6.  Correlation between tubocurarine requirements and plasma protein pattern.

Authors:  A Baraka; F Gabali
Journal:  Br J Anaesth       Date:  1968-02       Impact factor: 9.166

7.  A dose-response study of the anticoagulant and lipolytic activities of heparin in normal subjects.

Authors:  A C Asmal; W P Leary; F Thandroyen; J Botha; S Wattrus
Journal:  Br J Clin Pharmacol       Date:  1979-05       Impact factor: 4.335

Review 8.  Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

9.  Pharmacokinetics of theophylline in hepatic disease.

Authors:  A Mangione; T E Imhoff; R V Lee; L Y Shum; W J Jusko
Journal:  Chest       Date:  1978-05       Impact factor: 9.410

10.  Importance of blood-collection tubes in plasma lidocaine determinations.

Authors:  W W Stargel; C R Roe; P A Routledge; D G Shand
Journal:  Clin Chem       Date:  1979-04       Impact factor: 8.327

View more
  88 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences.

Authors:  G M Pacifici; A Viani
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

3.  Serum alpha-1-acid glycoprotein and protein binding of disopyramide in patients with congestive heart failure.

Authors:  A Nomura; H Yasuda; T Kobayashi; S Kishino; N Kohri; K Iseki; K Miyazaki
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 4.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 5.  Covalent and noncovalent protein binding of drugs: implications for hepatic clearance, storage, and cell-specific drug delivery.

Authors:  D K Meijer; P van der Sluijs
Journal:  Pharm Res       Date:  1989-02       Impact factor: 4.200

Review 6.  The pharmacokinetic behaviour of opioids administered during cardiac surgery.

Authors:  R Hall
Journal:  Can J Anaesth       Date:  1991-09       Impact factor: 5.063

7.  pH-dependency of basic ligand binding to alpha 1-acid glycoprotein (orosomucoid).

Authors:  S Urien; F Brée; B Testa; J P Tillement
Journal:  Biochem J       Date:  1991-11-15       Impact factor: 3.857

8.  Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.

Authors:  J E Bredesen; P Kierulf
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

9.  Disopyramide protein binding in plasma from patients with nephrotic syndrome during the exacerbation and remission phases.

Authors:  H Echizen; S Saima; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

10.  In vivo binding characteristics of carbamazepine and carbamazepine-10,11-epoxide to serum proteins in paediatric patients with epilepsy.

Authors:  Y Kodama; K Tsutsumi; M Kuranari; H Kodama; I Fujii; M Takeyama
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.